HealthDay on MSN23h
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionThe U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
A comparison between the Morningstar and Lipper mutual fund rating systems and why it’s important for investors to understand ...
Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback